Every 10-Q that HCA Healthcare, Inc. (HCA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HCA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCA filings page.
HCA Healthcare reported solid growth for the quarter ended June 30, 2026. Revenue rose to $20,230 million, up 8.7% year over year, and net income attributable to HCA increased to $1,699 million, or $7.62 per diluted share, driven by higher revenue per equivalent admission and modest volume gains.
Results were heavily influenced by Medicaid programs. The quarter included $1,372 million of incremental revenue and $829 million of other operating expenses from Florida’s directed payment program, producing about $400 million of incremental net benefit. At the same time, expiration of enhanced premium tax credits contributed to higher uninsured admissions and pushed total uncompensated care for the quarter to $15.076 billion.
Operating cash flow for the first six months fell to $4,349 million from $5,861 million, mainly due to working-capital effects from Medicaid state directed and supplemental payment programs and a $594 million increase in income tax payments. HCA continued returning capital, repurchasing 7.909 million shares at an average price of $447.53 and ending with $7.210 billion of remaining repurchase authorization, while total debt increased to $49,718 million.
HCA Healthcare’s first quarter of 2026 showed steady growth with rising capital returns but a tougher payer mix. Revenue increased 4.3% to $19.109 billion, driven by a 1.1% rise in equivalent admissions and a 3.1% increase in revenue per equivalent admission. Net income attributable to HCA inched up to $1.620 billion, while diluted EPS rose to $7.15 from $6.45, helped by share repurchases that reduced diluted shares to 226.652 million.
Operating cash flow strengthened to $2.014 billion from $1.651 billion, supporting $1.119 billion of capital spending and $1.571 billion of share repurchases for 3.157 million shares. However, the cost of total uncompensated care grew to an estimated $1.252 billion from $1.055 billion as uninsured admissions climbed following the expiration of enhanced premium tax credits. Total debt reached $48.023 billion, much of it long term, and HCA continued its dividend program, with a $0.78 per-share quarterly dividend declared for payment in June 2026.
HCA Healthcare reported stronger quarterly results. Revenue rose to $19.161 billion from $17.487 billion, and net income attributable to HCA increased to $1.643 billion, or $6.96 per diluted share, up from $1.270 billion, or $4.88. Growth was driven by a 6.1% increase in revenue per equivalent admission and a 3.2% rise in equivalent admissions. Same-facility revenue grew 9.2%.
For the nine months, revenue reached $56.087 billion versus $52.318 billion, with net income attributable to HCA of $4.906 billion. Operating cash flow was $10.277 billion, supported by higher earnings and lower cash taxes. The company repurchased 21.307 million shares at an average price of $352.40 and paid dividends.
HCA refinanced and simplified its capital structure: it issued $5.250 billion of senior notes, put in place an $8.000 billion senior unsecured revolver, and launched a $4.000 billion commercial paper program with $1.910 billion outstanding at quarter end. Total debt was $44.511 billion. Management highlighted policy risks tied to the OBBBA, including potential Medicare sequestration of up to 4% in early 2026 and scheduled Medicaid DSH cuts beginning October 1, 2025.